Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Core Insights - Nexalin Technology, Inc. has received regulatory approval for its Gen-2 Console ("SYNC"), a 15 milliamp neurostimulation device, for sale in Israel, marking a significant milestone for the company [1][2] - The approval in Israel enhances the global credibility of Nexalin's platform and supports its strategy for international market expansion, building on previous approvals in China, Brazil, and Oman [2][3] Company Overview - Nexalin Technology designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, with a focus on non-invasive and undetectable treatments [3] - The company's neurostimulation devices are designed to penetrate deep brain structures associated with mental health disorders, potentially offering enhanced patient responses without adverse side effects [3] Market Strategy - Following the regulatory clearance in Israel, Nexalin is accelerating discussions with regional distribution partners to launch commercial sales of its non-invasive mental health treatment solutions [2]